Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies

The frequent co-occurrence of kidney and heart diseases stems from complex, bidirectional pathophysiological interactions, which contribute to elevated morbidity and mortality and present significant challenges in clinical management.

This review examines the shared regulatory mechanisms underlying cardiorenal syndrome and synthesizes current evidence on emerging treatment options, including decongestion strategies, renin-angiotensin-aldosterone system inhibitors/ARNIs, sodium-glucose cotransporter-2 inhibitors, MRAs, and GLP-1 receptor agonists. Supported by large randomized trials, these novel adosing are redefining therapeutic approaches and heralding a new era in cardiorenal medicine. We also emphasize the necessity of incorporating both cardiac and renal endpoints in pivotal trials of new therapies and highlight the need for further research into the efficacy and safety of combination treatments.

Future clinical trials should adopt dual cardiorenal endpoints to better evaluate treatment effects. Combination therapies require rigorous investigation to establish optimal efficacy and safety profiles. These advances hold promise for optimizing multidisciplinary care, reducing disease burden, improving patient outcomes, and enhancing global health.